Top KOLs head Synexus therapeutic advisory boards
COPD and asthma was the focus of the first respiratory advisory board meeting which discussed current and relevant issues including new therapeutic targets, challenges in drug development and how to recruit patients and provide more information about participation in asthma and COPD clinical trials. Synexus are currently developing a patient specific asthma website as part of this initiative.
Dr Glynis Neagle Chief Medical Officer of Synexus noted, "There are numerous challenges facing drug developers who are pioneering new therapeutic indications in Respiratory Medicine including how to design studies with new agents in combination with current therapy and how best to assess the primary and secondary endpoints. Patients with asthma and COPD are very heterogenous populations and ensuring the correct patients are recruited and the optimal clinical outcomes included in the protocol are critical to the success of these studies. Through interaction with experts we can ensure that the Synexus team are completely up to date with current trends and thinking."
Synexus has a solid track record of bringing a new and innovative approach to the market and these advisory boards reflect another aspect of that strategy as well as their ability to not only recognise but react to the ever changing clinical trials industry.